Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 116


Effect of triple therapy in patients with asthma-COPD overlap

Ishiura Y, Fujimura M, Ohkura N, Hara J, Kasahara K, Ishii N, Tamaki T, Shimizu T, Nomura S.

Int J Clin Pharmacol Ther. 2019 Aug;57(8):384-392. doi: 10.5414/CP203382.


A comparison of the efficacy of once-daily fluticasone furoate/vilanterole with twice-daily fluticasone propionate/salmeterol in asthma-COPD overlap syndrome.

Ishiura Y, Fujimura M, Shiba Y, Ohkura N, Hara J, Kasahara K.

Pulm Pharmacol Ther. 2015 Dec;35:28-33. doi: 10.1016/j.pupt.2015.10.005. Epub 2015 Oct 22.


Effect of once-daily fluticasone furoate/vilanterol on 24-hour pulmonary function in patients with chronic obstructive pulmonary disease: a randomized, three-way, incomplete block, crossover study.

Boscia JA, Pudi KK, Zvarich MT, Sanford L, Siederer SK, Crim C.

Clin Ther. 2012 Aug;34(8):1655-66.e5. doi: 10.1016/j.clinthera.2012.06.005. Epub 2012 Jul 11.


Once-Daily Triple Therapy in Patients with COPD: Patient-Reported Symptoms and Quality of Life.

Tabberer M, Lomas DA, Birk R, Brealey N, Zhu CQ, Pascoe S, Locantore N, Lipson DA.

Adv Ther. 2018 Jan;35(1):56-71. doi: 10.1007/s12325-017-0650-4. Epub 2018 Jan 8.


Efficacy and safety of umeclidinium added to fluticasone furoate/vilanterol in chronic obstructive pulmonary disease: Results of two randomized studies.

Siler TM, Kerwin E, Sousa AR, Donald A, Ali R, Church A.

Respir Med. 2015 Sep;109(9):1155-63. doi: 10.1016/j.rmed.2015.06.006. Epub 2015 Jun 14. Erratum in: Respir Med. 2015 Nov;109(11):1493.


Comparative Efficacy of Once-Daily Umeclidinium/Vilanterol and Tiotropium/Olodaterol Therapy in Symptomatic Chronic Obstructive Pulmonary Disease: A Randomized Study.

Feldman GJ, Sousa AR, Lipson DA, Tombs L, Barnes N, Riley JH, Patel S, Naya I, Compton C, Alcázar Navarrete B.

Adv Ther. 2017 Nov;34(11):2518-2533. doi: 10.1007/s12325-017-0626-4. Epub 2017 Nov 1.


Efficacy and safety of once-daily inhaled umeclidinium/vilanterol in Asian patients with COPD: results from a randomized, placebo-controlled study.

Zheng J, Zhong N, Newlands A, Church A, Goh AH.

Int J Chron Obstruct Pulmon Dis. 2015 Sep 2;10:1753-67. doi: 10.2147/COPD.S81053. eCollection 2015.


A randomized, parallel-group study to evaluate the efficacy of umeclidinium/vilanterol 62.5/25 μg on health-related quality of life in patients with COPD.

Siler TM, Donald AC, O'Dell D, Church A, Fahy WA.

Int J Chron Obstruct Pulmon Dis. 2016 May 9;11:971-9. doi: 10.2147/COPD.S102962. eCollection 2016.


The effect of umeclidinium on lung function and symptoms in patients with fixed airflow obstruction and reversibility to salbutamol: A randomised, 3-phase study.

Lee L, Kerwin E, Collison K, Nelsen L, Wu W, Yang S, Pascoe S.

Respir Med. 2017 Oct;131:148-157. doi: 10.1016/j.rmed.2017.08.013. Epub 2017 Aug 14.


Dual Bronchodilator Therapy with Umeclidinium/Vilanterol Versus Tiotropium plus Indacaterol in Chronic Obstructive Pulmonary Disease: A Randomized Controlled Trial.

Kalberg C, O'Dell D, Galkin D, Newlands A, Fahy WA.

Drugs R D. 2016 Jun;16(2):217-27. doi: 10.1007/s40268-016-0131-2.


A randomized trial of once-daily fluticasone furoate/vilanterol or vilanterol versus placebo to determine effects on arterial stiffness in COPD.

Bhatt SP, Dransfield MT, Cockcroft JR, Wang-Jairaj J, Midwinter DA, Rubin DB, Scott-Wilson CA, Crim C.

Int J Chron Obstruct Pulmon Dis. 2017 Jan 19;12:351-365. doi: 10.2147/COPD.S117373. eCollection 2017.


Umeclidinium/vilanterol as step-up therapy from tiotropium in patients with moderate COPD: a randomized, parallel-group, 12-week study.

Kerwin EM, Kalberg CJ, Galkin DV, Zhu CQ, Church A, Riley JH, Fahy WA.

Int J Chron Obstruct Pulmon Dis. 2017 Feb 24;12:745-755. doi: 10.2147/COPD.S119032. eCollection 2017.


Once-daily umeclidinium/vilanterol 125/25 mcg in COPD: a randomized, controlled study.

Celli B, Crater G, Kilbride S, Mehta R, Tabberer M, Kalberg CJ, Church A.

Chest. 2014 May;145(5):981-991. doi: 10.1378/chest.13-1579.


Efficacy and safety of umeclidinium plus vilanterol versus tiotropium, vilanterol, or umeclidinium monotherapies over 24 weeks in patients with chronic obstructive pulmonary disease: results from two multicentre, blinded, randomised controlled trials.

Decramer M, Anzueto A, Kerwin E, Kaelin T, Richard N, Crater G, Tabberer M, Harris S, Church A.

Lancet Respir Med. 2014 Jun;2(6):472-86. doi: 10.1016/S2213-2600(14)70065-7. Epub 2014 May 14.


Efficacy and safety of once-daily umeclidinium/vilanterol 62.5/25 mcg in COPD.

Donohue JF, Maleki-Yazdi MR, Kilbride S, Mehta R, Kalberg C, Church A.

Respir Med. 2013 Oct;107(10):1538-46. doi: 10.1016/j.rmed.2013.06.001. Epub 2013 Jul 2.


Once-Daily Single-Inhaler Triple versus Dual Therapy in Patients with COPD.

Lipson DA, Barnhart F, Brealey N, Brooks J, Criner GJ, Day NC, Dransfield MT, Halpin DMG, Han MK, Jones CE, Kilbride S, Lange P, Lomas DA, Martinez FJ, Singh D, Tabberer M, Wise RA, Pascoe SJ; IMPACT Investigators.

N Engl J Med. 2018 May 3;378(18):1671-1680. doi: 10.1056/NEJMoa1713901. Epub 2018 Apr 18.


A phase III randomised controlled trial of single-dose triple therapy in COPD: the IMPACT protocol.

Pascoe SJ, Lipson DA, Locantore N, Barnacle H, Brealey N, Mohindra R, Dransfield MT, Pavord I, Barnes N.

Eur Respir J. 2016 Aug;48(2):320-30. doi: 10.1183/13993003.02165-2015. Epub 2016 Jul 13.


Improvements in lung function with umeclidinium/vilanterol versus fluticasone propionate/salmeterol in patients with moderate-to-severe COPD and infrequent exacerbations.

Donohue JF, Worsley S, Zhu CQ, Hardaker L, Church A.

Respir Med. 2015 Jul;109(7):870-81. doi: 10.1016/j.rmed.2015.04.018. Epub 2015 May 8.


The Efficacy and Safety of Once-daily Fluticasone Furoate/Umeclidinium/Vilanterol Versus Twice-daily Budesonide/Formoterol in a Subgroup of Patients from China with Symptomatic COPD at Risk of Exacerbations (FULFIL Trial).

Zheng J, Zhong N, Wang C, Huang Y, Chen P, Wang L, Hui F, Zhao L, Wang H, Luo L, Du X, Han Goh A, Lipson DA.

COPD. 2018 Jun-Aug;15(4):334-340. doi: 10.1080/15412555.2018.1481022. Epub 2018 Sep 28.


Supplemental Content

Support Center